
ADXN Valuation
Addex Therapeutics Ltd
- Overview
- Forecast
- Valuation
- Earnings
ADXN Relative Valuation
ADXN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADXN is overvalued; if below, it's undervalued.
Historical Valuation
Addex Therapeutics Ltd (ADXN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.76 is considered Undervalued compared with the five-year average of -1.57. The fair price of Addex Therapeutics Ltd (ADXN) is between 68.07 to 77.40 according to relative valuation methord. Compared to the current price of 7.90 USD , Addex Therapeutics Ltd is Undervalued By 88.39%.
Relative Value
Fair Zone
68.07-77.40
Current Price:7.90
88.39%
Undervalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
-0.90
EV/EBITDA
Addex Therapeutics Ltd. (ADXN) has a current EV/EBITDA of -0.90. The 5-year average EV/EBITDA is -1.01. The thresholds are as follows: Strongly Undervalued below -2.62, Undervalued between -2.62 and -1.82, Fairly Valued between -0.20 and -1.82, Overvalued between -0.20 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBITDA of -0.90 falls within the Historic Trend Line -Fairly Valued range.
-0.88
EV/EBIT
Addex Therapeutics Ltd. (ADXN) has a current EV/EBIT of -0.88. The 5-year average EV/EBIT is -1.07. The thresholds are as follows: Strongly Undervalued below -2.75, Undervalued between -2.75 and -1.91, Fairly Valued between -0.23 and -1.91, Overvalued between -0.23 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBIT of -0.88 falls within the Historic Trend Line -Fairly Valued range.
3.76
PS
Addex Therapeutics Ltd. (ADXN) has a current PS of 3.76. The 5-year average PS is 18.36. The thresholds are as follows: Strongly Undervalued below -26.49, Undervalued between -26.49 and -4.06, Fairly Valued between 40.79 and -4.06, Overvalued between 40.79 and 63.22, and Strongly Overvalued above 63.22. The current Forward PS of 3.76 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Addex Therapeutics Ltd. (ADXN) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.30. The thresholds are as follows: Strongly Undervalued below -5.06, Undervalued between -5.06 and -3.68, Fairly Valued between -0.92 and -3.68, Overvalued between -0.92 and 0.46, and Strongly Overvalued above 0.46. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Addex Therapeutics Ltd. (ADXN) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.94. The thresholds are as follows: Strongly Undervalued below -4.39, Undervalued between -4.39 and -3.16, Fairly Valued between -0.72 and -3.16, Overvalued between -0.72 and 0.51, and Strongly Overvalued above 0.51. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Addex Therapeutics Ltd (ADXN) has a current Price-to-Book (P/B) ratio of 76.66. Compared to its 3-year average P/B ratio of 17.95 , the current P/B ratio is approximately 326.98% higher. Relative to its 5-year average P/B ratio of 11.74, the current P/B ratio is about 552.89% higher. Addex Therapeutics Ltd (ADXN) has a Forward Free Cash Flow (FCF) yield of approximately -66.95%. Compared to its 3-year average FCF yield of -116.93%, the current FCF yield is approximately -42.75% lower. Relative to its 5-year average FCF yield of -87.83% , the current FCF yield is about -23.78% lower.
75.04
P/B
Median3y
17.95
Median5y
11.74
-66.95
FCF Yield
Median3y
-116.93
Median5y
-87.83
Competitors Valuation Multiple
The average P/S ratio for ADXN's competitors is 125.50, providing a benchmark for relative valuation. Addex Therapeutics Ltd Corp (ADXN) exhibits a P/S ratio of 3.76, which is -97.00% above the industry average. Given its robust revenue growth of 161.22%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADXN decreased by 27.16% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 173.68K to 453.71K.
The secondary factor is the Margin Expansion, contributed -48.77%to the performance.
Overall, the performance of ADXN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

AVXL
Anavex Life Sciences Corp
9.530
USD
+1.38%

REPL
Replimune Group Inc
5.680
USD
+3.46%

NTGR
NETGEAR Inc
27.090
USD
+0.33%

BJRI
BJ's Restaurants Inc
34.270
USD
+1.84%

MLR
Miller Industries Inc
44.260
USD
-0.49%

SWIM
Latham Group Inc
8.250
USD
+0.98%

PRA
ProAssurance Corp
23.770
USD
-0.34%

MEG
Montrose Environmental Group Inc
29.170
USD
-0.65%

BFLY
Butterfly Network Inc
1.590
USD
+2.58%

DAKT
Daktronics Inc
16.960
USD
+0.47%
FAQ

Is Addex Therapeutics Ltd (ADXN) currently overvalued or undervalued?
Addex Therapeutics Ltd (ADXN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.76 is considered Undervalued compared with the five-year average of -1.57. The fair price of Addex Therapeutics Ltd (ADXN) is between 68.07 to 77.40 according to relative valuation methord. Compared to the current price of 7.90 USD , Addex Therapeutics Ltd is Undervalued By 88.39% .

What is Addex Therapeutics Ltd (ADXN) fair value?

How does ADXN's valuation metrics compare to the industry average?

What is the current P/B ratio for Addex Therapeutics Ltd (ADXN) as of Aug 27 2025?

What is the current FCF Yield for Addex Therapeutics Ltd (ADXN) as of Aug 27 2025?

What is the current Forward P/E ratio for Addex Therapeutics Ltd (ADXN) as of Aug 27 2025?
